JP2014506452A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506452A5 JP2014506452A5 JP2013550573A JP2013550573A JP2014506452A5 JP 2014506452 A5 JP2014506452 A5 JP 2014506452A5 JP 2013550573 A JP2013550573 A JP 2013550573A JP 2013550573 A JP2013550573 A JP 2013550573A JP 2014506452 A5 JP2014506452 A5 JP 2014506452A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- fusion protein
- fragment
- derivative
- derived therefrom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 44
- 108020001507 fusion proteins Proteins 0.000 claims description 27
- 102000037865 fusion proteins Human genes 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 25
- 239000000816 peptidomimetic Substances 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 3
- 101800001415 Bri23 peptide Proteins 0.000 claims description 2
- 102400000107 C-terminal peptide Human genes 0.000 claims description 2
- 101800000655 C-terminal peptide Proteins 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 230000013595 glycosylation Effects 0.000 claims 6
- 238000006206 glycosylation reaction Methods 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 208000007502 anemia Diseases 0.000 claims 5
- 102000008154 Bone Morphogenetic Protein 6 Human genes 0.000 claims 4
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 238000005534 hematocrit Methods 0.000 claims 4
- 239000000710 homodimer Substances 0.000 claims 4
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 241000699802 Cricetulus griseus Species 0.000 claims 2
- 102000001554 Hemoglobins Human genes 0.000 claims 2
- 108010054147 Hemoglobins Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 2
- 230000013632 homeostatic process Effects 0.000 claims 2
- 230000000921 morphogenic effect Effects 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 239000002510 pyrogen Substances 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161434405P | 2011-01-19 | 2011-01-19 | |
| US61/434,405 | 2011-01-19 | ||
| PCT/US2012/021829 WO2012150973A1 (en) | 2011-01-19 | 2012-01-19 | Compositions for regulating iron homeostasis and methods of using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016158787A Division JP6466376B2 (ja) | 2011-01-19 | 2016-08-12 | 鉄恒常性を制御するための組成物およびそれを用いる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014506452A JP2014506452A (ja) | 2014-03-17 |
| JP2014506452A5 true JP2014506452A5 (cg-RX-API-DMAC7.html) | 2015-03-05 |
Family
ID=47107987
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550573A Pending JP2014506452A (ja) | 2011-01-19 | 2012-01-19 | 鉄恒常性を制御するための組成物およびそれを用いる方法 |
| JP2016158787A Expired - Fee Related JP6466376B2 (ja) | 2011-01-19 | 2016-08-12 | 鉄恒常性を制御するための組成物およびそれを用いる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016158787A Expired - Fee Related JP6466376B2 (ja) | 2011-01-19 | 2016-08-12 | 鉄恒常性を制御するための組成物およびそれを用いる方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9708379B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2665752B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2014506452A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102035357B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107022032A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2012251919B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2825163C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012150973A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110070242A1 (en) * | 2009-09-01 | 2011-03-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for Diagnosing and Treating Iron Dysregulation |
| WO2013090633A2 (en) * | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
| CN107459576A (zh) | 2011-12-14 | 2017-12-12 | 艾伯维德国有限责任两合公司 | 用于诊断和治疗铁相关病症的组合物和方法 |
| UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
| WO2017123642A1 (en) * | 2016-01-12 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis |
| CA3027651A1 (en) | 2016-06-15 | 2017-12-21 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6) |
| US20210107959A1 (en) * | 2018-01-03 | 2021-04-15 | Acceleron Pharma Inc. | Single-arm co-receptor fusion proteins and uses thereof |
| AU2020356575A1 (en) | 2019-09-27 | 2022-04-14 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| WO2021150937A1 (en) * | 2020-01-23 | 2021-07-29 | The Rockefeller University | Phase separation sensors and uses thereof |
| EP4149548A4 (en) | 2020-05-13 | 2024-05-08 | Disc Medicine, Inc. | ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| EP4359075A4 (en) * | 2021-06-21 | 2025-05-14 | Keros Therapeutics, Inc. | METHODS OF USING INHIBITORS OF ACTIVIN RECEPTOR TYPE II SIGNALING |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| EP1618131A2 (en) * | 2003-04-15 | 2006-01-25 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
| EP2335719B1 (en) * | 2005-02-16 | 2015-06-24 | The General Hospital Corporation | Use of hemojuvelin fusion proteins to regulate hepcidin-mediated iron metabolism |
| US7534764B2 (en) | 2005-06-29 | 2009-05-19 | The Regents Of The University Of California | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
| EP1806365A1 (en) * | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| US7528111B2 (en) | 2006-05-12 | 2009-05-05 | Bristol-Myers Squibb Company | Method of vaccinating subjects receiving immune modulating therapy |
| EP1862555A1 (en) | 2006-05-29 | 2007-12-05 | Klinikum der Universität Regensburg | Means and methods for diagnosing cancer or a corresponding predisposition |
| US8895002B2 (en) * | 2007-04-09 | 2014-11-25 | The General Hospital Corporation | Hemojuvelin fusion proteins and uses thereof |
| CN101307085B (zh) * | 2007-08-01 | 2012-06-13 | 香港理工大学深圳研究院 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
| EP2033971A1 (de) * | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung |
| US20100260785A1 (en) * | 2007-12-13 | 2010-10-14 | Gabriela Saborio | SARP-1 Fusion Proteins and Uses Thereof |
| EP2297197B1 (en) | 2008-05-29 | 2012-03-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof |
| WO2010056981A2 (en) * | 2008-11-13 | 2010-05-20 | Massachusetts General Hospital | Methods and compositions for regulating iron homeostasis by modulation bmp-6 |
-
2012
- 2012-01-19 JP JP2013550573A patent/JP2014506452A/ja active Pending
- 2012-01-19 CN CN201610908297.0A patent/CN107022032A/zh active Pending
- 2012-01-19 CN CN201280013021.6A patent/CN103649126B/zh not_active Expired - Fee Related
- 2012-01-19 CA CA2825163A patent/CA2825163C/en not_active Expired - Fee Related
- 2012-01-19 WO PCT/US2012/021829 patent/WO2012150973A1/en not_active Ceased
- 2012-01-19 US US13/980,666 patent/US9708379B2/en not_active Expired - Fee Related
- 2012-01-19 EP EP12779784.3A patent/EP2665752B1/en not_active Not-in-force
- 2012-01-19 KR KR1020137021394A patent/KR102035357B1/ko not_active Expired - Fee Related
- 2012-01-19 AU AU2012251919A patent/AU2012251919B2/en not_active Ceased
-
2016
- 2016-08-12 JP JP2016158787A patent/JP6466376B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-15 AU AU2017201782A patent/AU2017201782B2/en not_active Ceased
- 2017-07-17 US US15/651,988 patent/US10273273B2/en not_active Expired - Fee Related
-
2019
- 2019-04-16 AU AU2019202913A patent/AU2019202913A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506452A5 (cg-RX-API-DMAC7.html) | ||
| US9493530B2 (en) | FGF21 mutants comprising a mutation at position 98, 171 and/or 180 | |
| EP3004152B1 (en) | Designed ankyrin repeat proteins binding to hepatocyte growth factor | |
| US10610568B2 (en) | Compositions and methods of use for treating metabolic disorders | |
| KR102853359B1 (ko) | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 | |
| AU2013352363B2 (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
| KR102668200B1 (ko) | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 | |
| US10287336B2 (en) | Feline erythropoietin receptor agonists | |
| JP2016528295A5 (cg-RX-API-DMAC7.html) | ||
| RU2019134204A (ru) | Композиция, содержащая антитело, которое связывается с доменом ii her2, и его кислые варианты | |
| FI3596116T3 (fi) | Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä | |
| EP2585098B1 (en) | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders | |
| AU2012251919B2 (en) | Compositions for regulating iron homeostasis and methods of using same | |
| JP2019501647A5 (cg-RX-API-DMAC7.html) | ||
| JP2019506166A5 (cg-RX-API-DMAC7.html) | ||
| AU2016346870A1 (en) | Dual function proteins and pharmaceutical composition comprising same | |
| JP2015530390A5 (cg-RX-API-DMAC7.html) | ||
| KR20060022655A (ko) | 에리스로포이에틴 수용체에 결합하는 펩티드 | |
| JP2016183180A (ja) | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド | |
| EP3071215A2 (en) | Compositions and methods for treating pulmonary hypertension | |
| FI3774859T3 (fi) | Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät | |
| JP2008542399A (ja) | エリスロポエチンレセプターペプチドの処方および使用 | |
| WO2016110786A1 (en) | Solube fgfr3 decoys for treating skeletal growth disorders | |
| Ceaglio et al. | Improvement of in vitro stability and pharmacokinetics of hIFN-α by fusing the carboxyl-terminal peptide of hCG β-subunit | |
| WO2021247675A9 (en) | Coronavirus-binding agents and uses thereof |